pituitary imaging techniques have helped in the early diagnosis of TSH-secreting adenomas. 3, 4 Transsphenoidal surgery is the first-line treatment for these tumors. However, most studies, even recent papers describing remission rates of 0% to 55%, 7, 9, 22, 35, 38 report poor surgical outcomes due to relatively high frequencies of large adenomas, invasive adenomas, and/or markedly fibrous adenomas, although a steady decrease in the proportion of macroadenomas has been reported. 4, 32 Most TSH-secreting pituitary adenomas express a variable number of somatostatin receptors. Administering somatostatin analogs as a primary treatment or adjuvant to surgery is highly effective in reducing TSH secretion or shrinking these tumors, 3, 4, 11, 13, 31, 32 although published reports are limited by small sample sizes. The purpose of the current study was to investigate the clinicopathological features and outcomes of surgical treatment in patients with TSH-secreting tumors treated at our center.
Methods

Patient Population
A total of 92 patients diagnosed with TSH-secreting adenoma based on clinical and neuroimaging findings underwent pituitary surgery at Toranomon Hospital between December 1991 and May 2013. Two patients were excluded from the study because no TSH-secreting tumor was found. In one of these cases, a microadenoma was found during surgery, but it was immunoreactive for growth hormone (GH) and prolactin and not for TSH. In the other case, which involved a 15-year-old girl, an adenoma was suspected on the basis of MRI but no tumor was found during surgery and thyroid hormone resistance was verified by postoperative molecular biological analysis. 14 The hospital records of each of these 90 patients were reviewed.
These 90 cases of TSH-secreting adenomas represented only 2.7% of the 3276 pituitary adenomas that were surgically treated at our hospital during the overall study period. During the last 5 years of the study period, however, the rate increased to 4.0%, with 54 of 1351 cases of surgically-treated pituitary adenomas being TSH-secreting tumors.
This study was approved by the ethics committee at Toranomon Hospital, Tokyo.
Endocrine Studies
Blood basal levels of the anterior pituitary hormones (GH, prolactin, TSH, follicle-stimulating hormone [FSH] , and luteinizing hormone [LH] , a-subunit), and their target hormones (insulin-like growth factor 1 [IGF-1], free thyroxine [FT4], free triiodothyronine [FT3], testosterone, free testosterone, and estradiol) were measured preand postoperatively. Pituitary stimulation tests were also performed in some cases pre-and postoperatively using a combination of thyrotropin-releasing hormone (TRH) (500 mg), LH-releasing hormone (100 mg), and corticotropin-releasing hormone (100 mg). A chemiluminescent enzyme immunoassay (Lumipulse f or Lumipulse Presto a, Fujirebio Inc.) was used to measure TSH (normal range 0.54-4.26 mIU/ml), FT4 (normal range 0.72-1.52 ng/dl), and FT3 (normal range 2.29-4.17 pg/ml). The a-subunit was also measured using a commercial immunometric assay (normal range 0.16-0.36 ng/ml in males, 0.04-0.66 ng/ml in females). The tumor was considered to be TRHresponsive if the TSH level increased more than twice the basal level in response to the TRH stimulation test. Cosecretion of GH was identified by supranormal IGF-1 levels and a lack of GH suppression in response to a 75-g glucose tolerance test. Associated hyperprolactinemia was identified when tumor cells showed prolactin immunopositivity, whereas an immunonegative response to prolactin was considered a stalk-section effect. GH hypersecretion was considered to be in complete remission when fulfilling the conditions of a normal basal GH level, normal GH suppression (GH nadir < 0.4 ng/ml) during glucose tolerance testing, and normal IGF-I levels based on age and sex.
12 GH, IGF-1, and prolactin assays were performed according to our previously reported methods. 37 Octreotide (100 mg administered subcutaneously) or bromocriptine (2.5 mg by mouth) tests were performed to investigate TSH responses to somatostatin analogs or dopamine agonists. TSH was considered suppressed if it decreased to less than 50% of the basal level.
Plasma TSH, FT3, and FT4 levels were measured 2-4 times during the 2-week hospital stay after surgery and at 3 and 6 months after surgery. Patients were followed up every 6 months at our outpatient department or by the referring hospitals.
MRI Study and Tumor Size
MRI studies were obtained before and after surgery and once a year thereafter using a 1.5-or 3.0-T scanner with injection of gadolinium. The maximum diameter of each tumor was measured, and the tumors were classified as microadenomas (maximum diameter < 10 mm) or macroadenomas (maximum diameter ≥ 10 mm). Tumor volume was calculated according to the Di Chiro and Nelson formula: volume = height × length × width × 0.5233. 20 Lateral tumor growth was assessed by Knosp classification. 16 A thyroid ultrasound study was also performed preoperatively in some patients to assess the condition of the thyroid gland.
Surgical Procedures
In all cases, surgery was performed by the same surgeon (S.Y.), who has performed more than 2500 pituitary surgeries. The same transsphenoidal surgical procedure was basically used for each case. Endoscopy was employed as an adjuvant to microscopic surgery after the year 2000, and purely endoscopic surgery has been advocated since 2012. The tumors were aggressively attacked and as much tumor tissue was removed as possible, even in the presence of cavernous sinus invasion, by wide opening of the sella to expose the floor of the sinus regardless of microscopic or endoscopic approach. Our surgical procedure for removing these tumors was similar to that for removing intracranial meningiomas. If the tumor had a pseudo-capsule or was firm elastic or hard in consistency, it was carefully dissected from the surrounding normal pituitary and/or medial wall of the cavernous sinus and shrunk by blunt or sharp piece-by-piece intracapsular removal to enhance further dissection of tumor from the surrounding normal structures (Fig. 1) . Cavernous sinus invasion can be roughly divided into 2 types: partial invasion and diffuse invasion. Tumor invades the medial wall of the cavernous sinus and protrudes into it to some extent in the former type, and such partial cavernous sinus invasion was strictly confirmed in this study by direct observation of the entire medial wall when we dissected and excised tumor from the medial wall of the cavernous sinus. In contrast, tumor extends into the lateral cavernous sinus compartment and encases the internal carotid artery completely in the latter type, which corresponds to tumors classified as Knosp Grade 4 on MRI and easily judged as invading the cavernous sinus. In addition, we performed extended transsphenoidal surgery or a simultaneous transsphenoidal and transcranial combined approach to treat large/giant multilobulated invasive adenomas.
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Criteria for Remission and Recurrence
Patients were considered to be in complete remission if the tumor was completely removed during surgery, as determined by postoperative MRI, and the serum TSH, FT3, and FT4 levels were normalized. In cases of associated cosecretion of GH and/or prolactin, remission was not considered to be complete if GH and/or prolactin levels were not normalized, even if the case fulfilled the criteria of remission of TSH-secreting adenoma. The patient was considered to have a recurrence if clinical, biochemical, and/or neuroimaging signs of tumor activity were detected after complete remission.
Histological and Immunocytochemical Studies
Specimens were obtained during surgery and fixed in 10% buffered formaldehyde, dehydrated in graded ethanol, embedded in paraffin, and studied using routine histological methods such as immunohistochemistry. Microsections were stained with hematoxylin and eosin. Immunocytochemical studies were performed as previously described. 36 Antigen retrieval was not performed routinely for immunostaining of anterior pituitary hormones. However, specimens from 3 tumors that showed negative immunostaining for TSH underwent additional proteinase K treatment (DAKO, 1:50, 9 minutes). Ki-67 labeling was performed using antibodies (MIB-1; clone 30-9 [product no. 790-4286, Ventana]) for assessing the aggressiveness of the tumor. We counted a mean of 1000 tumor cells per case, and the results were expressed as a percentage of tumor cells with positively stained nuclei. Only nuclei with a strong positive label were counted.
Statistical Analysis
Data were expressed as mean ± SD. Statistical analysis was performed using JMP software (version 9.0.2, SAS Institute Inc.). Logistic regression analysis was performed for all continuous data. Categorical variables were analyzed using chi-square tests. Multivariate stepwise logistic regression analysis was performed to detect independent predictors of complete remission rate using factors that had significant associations in univariate analysis. A p value less than 0.05 was considered statistically significant.
Results
Patient Characteristics
Demographic and clinical characteristics of our patients, including tumor characteristics, are summarized in Table 1 . The median age of our patients at the time of surgery was 42 years (range 11-74 years). Forty-seven patients (52%) were female. Signs and symptoms of hyperthyroidism were found in 83 patients (Table 1) . Six patients had been diagnosed with primary hyperthyroidism before being referred to our hospital. One of these patients had a previous history of radioactive iodine thyroid ablation, and 5 had undergone antithyroid agent treatment. Visual disturbance was noted in 13 patients (14%). Acromegalic features were observed in association with hyperthyroidism in 14 patients (16%), and menstrual irregularity was found in 16 of 30 female patients less than 50 years old. Of the 11 cases of hyperprolactinemias, 6 were due to hypersecretion of prolactin from the tumor itself. Multiple endocrine neoplasia was noted in only 1 patient (1%).
Sixteen patients (18%) had a microadenoma, and 74 patients (82%) had a macroadenoma (Table 1) . Microadenomas occurred more frequently in the more recent half of our cases (occurring in 12 of 45 cases) than in the first half of our cases (occurring in 4 of 45) (p = 0.0274). Most macroadenomas were intrasellar or they extended up to the chiasmatic cistern. Tumor invasion into the cavernous sinus was confirmed in 21 patients (23%) during surgery. Sixty-seven tumors (74%) were firm elastic or hard in consistency.
Baseline Laboratory Findings
Syndrome of inappropriate TSH secretion (SITSH) (normal or high serum TSH level despite high serum FT4 and/or FT3 levels) was found in 87 patients. Of the 3 patients with euthyroidism, one had taken an antithyroid drug (TSH level 98.4 mIU/ml), one had been treated with thyroid hormone after radioactive I 131 thyroid ablation, and one had undergone repeat surgery for the regrowth of a TSH-secreting adenoma that had been surgically treated in another hospital. Excluding these 3 patients, the median TSH level was 3.08 mIU/ml (interquartile range [IQR] 1.82-4.33, normal range 0.54-4.26). TSH was above normal in 26 patients (30%) and normal in 61 patients (70%). The median FT4 level was 2.11 ng/dl (IQR 1.71-2.73 ng/dl, normal range 0.72-1.52 ng/dl) and FT3 was 5.85 pg/ml (IQR 4.85-7.81 pg/ml, normal 2.29-4.17 pg/ml). Serum a-subunit levels were measured in 58 patients and were above normal in 44 (76%). There were no significant correlations between serum TSH values and FT4 levels (coefficient of correlation 0.58), TSH values and tumor volumes (coefficient 0.16), or FT4 levels and tumor volumes (coefficient 0.02). Six (13%) of 45 patients had a TSH response (more than twice the basal level) to TRH loading and 19 patients had a TSH response more than 1.5 times the basal level. TSH decreased to less than 50% of the basal level in 49 (71%) of 69 patients administered 100 µg octreotide subcutaneously and 4 (17%) of 24 patients administered 2.5 mg bromocriptine orally.
Preoperative Medical Treatment
Somatostatin analogs have been commercially available since July 1989, but they have not been approved as a treatment for TSH-secreting adenoma in Japan. Therefore, somatostatin analogs were not administered in some cases because of economic reasons. Moreover, they were also not used in cases of small adenomas associated with a slight elevation of serum FT4 level and no marked signs and symptoms of thyrotoxicosis. As a result of a variety of circumstances as mentioned above, preoperative octreotide treatment was administered in 48 cases in this series. In 25 of these 48 cases, the patients were treated with short-acting octreotide (administered subcutaneously 3 times a day, total daily dose 300 mg, for 1 week before surgery), and in the other 23 cases, they were treated with long-acting octreotide (administered intramuscularly at a dosage of 20 mg either 1 month before surgery or 1 and 2 months before surgery). In an additional case, treatment with long-acting octreotide was not initiated because the patient experienced severe abdominal pain after subcutaneous injection of octreotide. In the 48 patients who received octreotide, the median duration between the start of octreotide treatment and surgery was 34.1 days. Preoperative normalization of FT4 was achieved in 40 (83%) of the 48 patients treated with octreotide and tumor shrinkage by more than 20% was also found in 24 (55%) of 44 patients in whom pre-and post-treatment MR images were available. Stratification by presence or absence of hormonal normalization or tumor shrinkage showed no significant difference in pretreatment serum TSH ( Patients who could not be treated with or did not respond sufficiently to preoperative octreotide were treated with antithyroid drugs and/ or inorganic iodine a few days before surgery to prevent development of perioperative thyroid storm.
Surgical Outcomes
A total of 84 patients received primary surgery, and 6 underwent repeated surgery due to the recurrence or persistence of the tumor (after primary surgery performed in another hospital). Conventional transsphenoidal surgery, extended transsphenoidal surgery, or a simultaneous combined supra-and infrasellar approach was performed in 85, 2, and 3 patients, respectively (Figs. 1 and 2). Surgery was defined as successful if total removal of the tumor and complete endocrinological remission were achieved. By this definition, surgery was successful in 76 patients (84%), including all 16 (100%) of the patients with microadenomas (including one with cavernous sinus invasion), 60 (81%) of the 74 patients with macroadenomas, and 8 (38%) of the 21 patients with cavernous sinus invasion. With respect to Knosp grade, surgery was successful in 34 (94%) of 36 patients with Knosp Grade 0 tumors, all 24 (100%) of those with Grade 1 tumors, 12 (86%) of the 14 with Grade 2 tumors, 6 (75%) of the 8 with Grade 3 tumors, and none (0%) of the 8 with Grade 4 tumors. Following the successful surgeries, serum TSH levels typically decreased below the normal range within 1-3 days, reached their lowest point 1-2 weeks later, and gradually increased back to the normal range after several months. In contrast, serum FT4 levels tended to be normal or above normal during the early postoperative period (1-2 weeks) and decreased below the normal range for up to 6 months after surgery. Postoperative thyroid hormone replacement (50 mg/day levothyroxine sodium hydrate) was needed in 11 (14%) of the 76 patients with successful surgery; however, it was needed only on a temporary basis in 9 of these cases. Only 2 patients still required thyroid hormone replacement at final follow-up. No recurrence of the tumor and/or reappearance of SITSH occurred in the 76 patients in whom surgery was successful (median follow-up period 2.8 years).
The surgeries in the remaining 14 patients were considered to be unsuccessful because the criteria for remission were not met. The details of clinical characteristics and follow-up results of these 14 patients are summarized in Table 2 . One of these 14 patients (Case 7) died of malignant hyperthermia syndrome 2 weeks after a simultaneous combined approach for the treatment of her lobulated giant adenoma (no cavernous sinus invasion, Knosp Grade 0). Eight patients had a pure TSH-secreting adenoma, 5 had a TSH-and GH-secreting adenoma, and one had a TSH-and prolactin-secreting adenoma. Cavernous sinus invasion was diagnosed in all but 1 case, although in another case (Case 10), the tumor was assessed as Knosp Grade 0 on the basis of the preoperative MRI study. Euthyroidism was achieved in 10 patients in this group of 14, although in 9 of these 10 cases postoperative MRI showed some residual tumor in either the cavernous sinus (in 8 cases) or the suprasellar region (in Case 7); the patient in Case 10 had no residual tumor. Postoperative endocrine testing showed persistence of abnormal GH dynamics in 4 of the 5 patients (Cases 10-13 in Table  2 ) with TSH-and GH-secreting adenomas, although testing demonstrated euthyroidism postoperatively in 4 cases also (Cases 9, 10, 12, and 13). In 11 of 14 cases, the patients received adjuvant treatments such as postoperative medication and/or radiation. Residual tumor masses and hypersecretion of hormones were controlled adequately in 9 patients, whereas SITSH was still present in 1 patient (Case 2) and a supranormal IGF-1 level persisted in 1 patient (Case 13) following the treatments. Of the surviving 2 patients who did not undergo adjuvant treatment postoperatively (Cases 5 and 6), one did not experience tumor regrowth or SITSH (Case 5), whereas the other (Case 6) showed SITSH (slight elevation of FT4 levels) 2.5 years after surgery.
Analysis of Preoperative Factors Influencing Surgical Results
The association between preoperative variables (age, sex, GH level, year of surgery, concomitant GH secretion, preoperative TSH, FT3, and FT4 levels, visual disturbance, tumor size, cavernous sinus invasion, Knosp grade, and tumor consistency) and surgical outcome is presented in Tables 3 and 4 . The patients were classified into 2 groups based on the surgical results: a successful-surgery group (76 patients), in which the criteria for cure were fulfilled, and an unsuccessful-surgery group (14 patients). Univariate analysis showed that cosecretion of GH, visual disturbance, tumor size, Knosp grade, and cavernous sinus invasion were significantly correlated with surgical outcome, whereas age, sex, year of surgery, tumor consistency, and preoperative serum TSH, FT3, and FT4 levels were not. According to multivariate analysis using the logistic regression model, cavernous sinus invasion was the strongest predictor of the surgical outcome, although tumor size was also an independent predictor.
Surgical Complications
One patient died of malignant hyperthermia syndrome 2 weeks after surgery despite appropriate intensive care. In addition, 3 patients died during the follow-up period of conditions unrelated to the adenoma surgery (liver insufficiency, cerebral infarction, and lung cancer, with death occurring 3, 4, and 6 years after surgery, respectively). Postoperative CSF leak occurred in 3 patients. One documented case of meningitis (1.1%) occurred secondary to the CSF leakage and 2 patients required reoperation for repair of CSF leakage. Diabetes insipidus occurred in 10 patients (11%) in the immediate postoperative period and was permanent in 2 (2.2%) patients, who required long-term desmopressin treatment. Nine patients developed delayed hyponatremia postoperatively due to inappropriate antidiuretic hormone (ADH) secretion. One patient had anosmia and one had acute sinusitis after surgery.
Postoperative Pituitary Function
Follow-up pituitary function was investigated in all but the 1 patient who died 2 weeks after surgery. A total of 74 (83%) of 89 patients remained eupituitary after surgery. Of the 15 patients with pituitary impairment, 5 patients were considered to have panhypopituitarism, 6 had GH deficiency, 2 had LH/FSH and adrenocorticotropic hormone (ACTH) deficiency, 1 had ACTH deficiency, and 1 had ADH deficiency.
Histological Findings
Specimens from all but 3 of our patients showed positive immunostaining for TSH, and pretreatment with proteinase K led to positive immunostaining in the 3 TSH-negative cases. GH, prolactin, and both GH and prolactin were detected in specimens from 32, 9, and 24 patients, respectively. Ki-67 immunohistochemistry was carried out in 73 cases, and the Ki-67 labeling index was less than 1% in 40 patients (55%), between 1% and 3% in 31 patients (42%), and greater than 3% in 2 patients (3%). The Ki-67 labeling index did not differ significantly between successful and unsuccessful surgical outcomes (p = 0.257) or noninvasive and invasive tumors (p = 0.460).
Discussion
Clinical Characteristics
According to Beck-Peccoz et al., the number of reported TSH-secreting adenomas has tripled in the last decade, primarily due to the introduction of ultrasensitive TSH immunometric assays and improved practitioner awareness.
3,4 TSH-secreting tumors account for less than 2% of all pituitary adenomas, according to some reports. 1, 27 However, a recent epidemiological investigation in Sweden showed an increased incidence of TSHsecreting adenoma from 0. These tumors represented only 2.7% of 3276 pituitary adenomas that were surgically treated at our hospital during the overall study period. However, the proportion of tumors that were TSH-secreting adenomas increased to 4.0% (54 of 1351 cases) during the last 5 years of our study period. The increase in the number of surgical cas- es at Toranomon Hospital may be partially due to this institution's establishment of a pituitary center in 2005, the first such center to be established in Japan.
The prevalence of microadenomas is progressively increasing due to improved thyroid function testing and awareness among endocrinologists and general practitioners. Although microadenomas accounted for fewer than 15% of cases before 1996, 32 Beck-Peccoz and Persani reported that 8 (62%) of 13 TSH-secreting tumors were microadenomas in cases diagnosed after 1996. 3 In our study, the overall frequency of microadenomas was 18%, but it was significantly higher in the more recently diagnosed cases (12 of 45 cases) than in the earlier group (4 of 45 cases) (p = 0.0274). In approximately 30% of cases, TSH-secreting adenoma is misdiagnosed as primary hyperthyroidism and the patients undergo thyroid ablative treatment such as administration of antithyroid medication, thyroidectomy, or radioactive iodine thyroid ablation prior to discovery of the pituitary lesion. 4, 7, 32 However, only 6 of our patients had undergone inappropriate treatment. TSH-secreting adenomas have been reported in patients ranging from 8 to 84 years of age (most are in the 5th or 6th decade of life), with equal frequency in men and women, 3 which agrees with our findings. Similar to other reports, 21, 34 one case was associated with previous Hashimoto's thyroiditis and hypothyroidism and one case was associated with multiple endocrine neoplasia Type 1.
Patients with TSH-secreting adenomas present signs and symptoms of hyperthyroidism, but they are usually mild or clinically silent. Seven of our patients did not show signs or symptoms of thyrotoxicosis, even though they had supranormal FT4 concentrations. TSH-secreting adenomas are often plurihormonal, and testing demonstrated plurihormonal immunostaining in 75 (83%) of 90 cases. Hypersecretion of GH and/or prolactin (PRL), resulting in acromegaly and/or amenorrhea/galactorrhea syndrome, respectively, are most common and are present in about 30% of patients with TSH-secreting adenomaa. 3, 30 We similarly found cosecretion of GH and/or PRL in 22% of 90 patients. However, we did not find any associations with LH/FSH or ACTH hypersecretion in our series, possibly because GH and PRL cells share common transcription factors, such as Prop-1 and Pit-1, with TSH cells.
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Differential Diagnosis
Elevated thyroid hormone concentrations in the presence of normal or supranormal TSH levels is termed "inappropriate TSH secretion" and is the biochemical characteristic of central hyperthyroidism. Along with measurement of serum TSH and thyroid hormone concentrations, serum a-subunit measurement and both T3 suppression and TRH tests are recommended to increase the specificity and sensitivity of diagnosis. 1, 4 We found elevated serum a-subunit levels in 76% of patients and a blunted TSH response (less than two times the basal value) to a pituitary stimulation test in 87% of patients examined in our study. In general, these additional data did not help us in further diagnosing TSH-secreting adenomas, although the T3 suppression test was not performed in most patients. Furthermore, TRH is no longer available in the US, 7 and a-subunit assay is neither covered by medical insurance nor performed in Japan. In contrast, all but 3 patients (with a history of long-term antithyroid drug treatment, radioactive I 131 thyroid ablation, or previous pituitary surgery) showed SITSH when first diagnosed at Toranomon Hospital. SITSH and identification of a definite pituitary adenoma on MRI are key factors for diagnosis of a TSH-secreting adenoma. Losa et al. 18 also concluded that unsuppressed TSH levels in conjunction with clinical and biochemical hyperthyroidism should prompt a neuroimaging study to document the presence of a pituitary mass. Differentiating true SITSH from pseudo-SITSH and subsequently distinguishing between TSH-secreting adenoma and thyroid hormone resistance are essential for an accurate diagnosis. Pseudo-SITSH may be caused by acute elevation of FT4 or FT3 levels in the early phase of destructive thyroiditis or recurrence of primary hyperthyroidism, levothyroxine sodium hydrate treatment for hypothyroidism, methodological interferences, or familial dysalbuminemic hyperthyroxinemia. 3, 4 Repeat measurement of TSH, FT4, and FT3 using different assay methods may help identify true SITSH when the diagnosis is uncertain. 3, 4 Thyroid hormone resistance should be considered, and the thyroid hormone receptor, beta (THRB) gene should be examined first when a patient has an uncertain diagnosis of adenoma on MRI, a neurodevelopmental disorder and/or impaired bone growth, or a first-degree relative with similar biochemical characteristics. 28 
Surgical Treatment
The first-line therapy for patients with TSH-secreting adenomas, which was applied in the majority of our cases, is a transsphenoidal resection of the tumor to remove neoplastic tissues and restore normal pituitary/thyroid function. Although previous studies have shown the surgical outcome to be poor 7, 9, 23, 34, 35, 38 (Table 5) , we were able to achieve complete remission for 76 (84%) of the 90 patients in our study, including all 16 of the patients with microadenomas, 60 (81%) of the 74 with macroadenomas, and 8 (38%) of the 21 with cavernous sinus invasion. The different results may be partially explained by different criteria of remission and the small number of patients who received thyroid-targeted treatments among the studies. Aggressive and invasive macroadenomas are more frequently found in patients with previous thyroid ablation. 1 Our approaches of aggressively attacking the tumors with cavernous sinus invasion and using extended transsphenoidal sugery or a simultaneous combined approach for the giant adenomas may have also improved our surgical removal rate.
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Poor surgical outcome may be related to fibrosis, cavernous sinus invasion, or large tumor size. However, the frequencies of macroadenoma (82%) and cavernous sinus invasion (23%) in our study were similar to previous reports (macroadenoma, 45%-100%; cavernous sinus invasion, 25%-28%).
4,7,32 TSH-secreting adenomas are more often fibrotic than other types of pituitary tumors, 4, 29, 32 and fibrotic characteristics were present in 74% of our cases. Fibrosis may worsen surgical results in TSH-secreting adenomas. 4, 32, 35 For example, Socin et al. showed that while 60% of the tumors have a soft consistency that allows them to be gently removed or aspirated, the remaining tumors have fibrotic characteristics and are difficult to excise.
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The prognostic factors for surgical treatment of TSHsecreting adenomas have not been identified because these tumors are relatively rare and most surgical studies investigate a small number of cases. 19 Our study was the first to investigate preoperative factors that predict surgical outcome in a large number of cases at a single center. We confirmed that cavernous sinus invasion and tumor size, but not tumor consistency, were significant predictors of unsuccessful surgery. Our ability to successfully remove hard fibrous tumor may be one reason why we had a relatively high remission rate (84%) compared to other studies. Fibrous hard tumors do not always cause poor surgical outcomes and may be easier to remove completely. Exposing a smooth line of cleavage between the pituitary and/or the inner wall of the cavernous sinus and reducing the tumor size using tumor forceps and microscissors or an ultrasonic aspirator allows further dissection of the hard thick capsule from the surrounding structure. Thus, the surgeon can excise the remaining tumor en bloc (Fig. 1) . This microsurgical removal technique, similar to that used for meningiomas, may be preferable to conventional methods used for ordinary soft adenomas, such as a suction and curette. Most neurosurgeons believe that fibrous adenoma is difficult or impossible to remove completely. Changing the term for a firm elastic or hard pituitary adenoma from "fibrous adenoma" to "meningioma-like adenoma" may therefore change neurosurgeons' approach for tumor removal, as they may be less likely to remove a meningioma-like tumor by suction and curette. Further studies should investigate why fibrotic changes occur more frequently in TSH-secreting adenomas than in other types of adenomas, although overexpression of basic fibroblast growth factor may be involved in the development of fibrosis in these tumors.
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Preoperative Medical Treatment
Medical treatment of TSH-secreting adenoma has been significantly improved by the use of somatostatin analogs. The efficacy of this treatment in the present series is similar to that in previous reports. 3, 4, 11, 13, 31, 32 Preoperative octreotide administration led to FT4 normalization in 40 (83%) of 48 cases and tumor shrinkage in 24 (55%) of 44 cases in this study. These results are similar to those of Beck-Peccoz and Persani, who report that octreotide reduces TSH levels in more than 90% of cases, restores a euthyroid state in the majority of patients, and decreases tumor size as assessed by imaging in nearly half of patients. 2 Therefore administration of octreotide, rather than antithyroid drugs and/or an iodine compound, can help not only by restoring euthyroidism preoperatively in patients with SITSH, decreasing the risk of perioperative thyroid storm, but also by reducing tumor size, which may improve surgical outcome.
It has been reported in the literature that surgical cure rates for patients with TSH-secreting adenomas are low (0%-63%, Table 5 ), tumors seem refractory to irradiation, and the majority of patients are still in need of medical therapy after unsuccessful surgery. Given the high efficacy of somatostatin analogs (normalization of thyroid hormone levels in 95% and tumor shrinkage in 40% of the patients 4 ), van Varsseveld et al. concluded that primary medical therapy may be considered in virtually all patients with TSH adenomas, except in those with optic chiasm compression. 35 However, when we take into account the fact that somatostatin analogs are expensive and treatment must be continued over a long period of time once started, surgery should be the first choice of treatment in patients with TSH-secreting adenomas as in patients with acromegaly or Cushing's disease if we can achieve surgical cure rates in the range of 60%-85%, which is almost similar to those of other types of functioning pituitary adenomas. Our current study can clearly demonstrate that a high surgical cure rate (84%) can be achieved by earlier proper diagnosis of TSH-secreting adenomas and aggressive tumor removal with adequate surgical approaches for various types of tumors. However, as in the treatment of acromegaly, primary medical therapy may be recommended when there is a low probability of a surgical cure (for example, in cases of tumors with cavernous sinus invasion lateral to the carotid artery or large extrasellar tumors with no evidence of central compressive effects), the risk of surgery is quite high, or patients do not want to undergo surgery. 2 
Surgical and Follow-Up Results
Residual tumor was confirmed by postoperative MRI in 13 of the 14 patients with an unsuccessful surgical outcome. Only 4 patients exhibited SITSH after surgery, whereas subnormal TSH levels with euthyroidism were found in the remaining 10 patients. Therefore, low TSH levels in the early postoperative period may not predict the success of the surgery. Cosecretion of GH, which was one of the unfavorable factors affecting surgical outcome in our study, was found in 5 of 14 unsuccessful cases. Endocrine data did not meet the criteria for remission in four patients, whereas one fulfilled the criteria for cure of acromegaly despite the presence of residual tumor in the left cavernous sinus. Some tumors may secrete hormones inefficiently, allowing for biochemical normalization despite tumor residual. Such discrepancy has been reported and highlights the lack of imaging criteria for characterizing remission of GH adenomas. 12, 26 Laws et al. reported that 9 patients with macroadenoma undergoing surgery for TSH-secreting adenoma had postoperative remnants, and all experienced a relapse of hyperthyroidism despite initial biochemical stabilization in 2 cases. 17 In contrast, 9 of the 11 patients who underwent postoperative medical and/or radiation treatment in our study had good control of hypersecretion of hormones and residual tumor during the follow-up period. This suggests that these adjuvant therapies normalized TSH-FT4 levels and/or prevented tumor regrowth and should be administered in patients in whom surgery has not been successful. None of the remaining 76 patients who had a successful surgery experienced relapse during the follow-up period.
Few reports describe postoperative thyroid hormone replacement after surgery. Most of the patients in our study with a successful surgery experienced slight or mild postoperative hypothyroidism for several months. However, temporary thyroid hormone replacement was needed in only 11 patients (14%), suggesting that thyroid hormone replacement is unnecessary in most patients even after successful surgery.
Surgical Complications and Histology
Major complications occurred in 4 cases (6%). One patient developed malignant hyperthermia syndrome and 3 had postoperative CSF leaks. Similar to previous findings, 33 various degrees of pituitary dysfunction developed in 15 patients (17%), and delayed hyponatremia was found in 9. No patient experienced perioperative thyroid storm in our study, possibly due to our preoperative procedures for correcting hyperthyroidism.
The proliferation marker Ki-67 is often used to evaluate invasiveness and recurrence of a tumor. 25 However, the Ki-67 labeling index was not significantly different between successful and unsuccessful surgeries (p = 0.257) or noninvasive and invasive tumors (p = 0.460) in this study, supporting other reports indicating that the prognosis cannot be predicted based on the Ki-67 labeling index alone. 
Conclusions
Although this is a retrospective case series and there may be some limitations of retrospective analysis, including selection bias for patient referral, changes in treatment modalities over time, or potential inaccuracy of various objective measures, we were able to make the following conclusions on the basis of in this study. We found that TSH adenomas have increased in frequency over the past 5 years and are more commonly found at the microadenoma stage. The improved success rate of surgery in this series is due to earlier diagnosis and smaller tumors. In addition, our surgical strategies, including extracapsular removal of hard or solid adenomas, aggressive attack of tumors with cavernous sinus invasion, and extended transsphenoidal surgery or simultaneous combined approach for large/giant multilobulated adenomas, may contribute to our superior results (higher rate of success combined with acceptable complication rate) in comparison with previous reports.
